muraglitazar has been researched along with Bladder Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brito, JP; Gionfriddo, MR; Leppin, AL; Montori, VM; Morey-Vargas, OL; Murad, MH | 1 |
| Arnold, LE; Cano, M; Cohen, SM; Dominick, MA; Moehlenkamp, JD; Sanderson, TP; Schilling, BE; Tannehill-Gregg, S; Van Vleet, T; Waites, CR; White, MR | 1 |
1 review(s) available for muraglitazar and Bladder Cancer
| Article | Year |
|---|---|
Systematic reviews to ascertain the safety of diabetes medications.
Topics: Acidosis, Lactic; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractures, Bone; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Male; Meta-Analysis as Topic; Metformin; Oxazoles; Pancreatic Neoplasms; Risk Assessment; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2014 |
1 other study(ies) available for muraglitazar and Bladder Cancer
| Article | Year |
|---|---|
Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action.
Topics: Animals; Antimetabolites; Apoptosis; Area Under Curve; Bromodeoxyuridine; Calcium; Carcinogens; Cell Proliferation; Citrates; Electrolytes; Glycine; Hydrogen-Ion Concentration; Immunohistochemistry; Male; Microscopy, Electron, Scanning; Organ Size; Oxalates; Oxazoles; Phosphates; PPAR alpha; PPAR gamma; Proteinuria; Rats; Rats, Sprague-Dawley; Spectrometry, X-Ray Emission; Urinary Bladder Neoplasms; Urolithiasis; Urothelium | 2006 |